[1] MADER R, VERLAAN JJ, BUSKILA D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol. 2013;9(12):741-750. 
[2]	FORESTIER J, ROTES-QUEROL J. Senile ankylosing hyperostosis of the spine. Ann Rheum Dis. 1950;9(4):321-330. 
[3] RESNICK D, NIWAYAMA G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology. 1976;119(3):559-568. 
[4]	TERZI R. Extraskeletal symptoms and comorbidities of diffuse idiopathic skeletal hyperostosis. World J Clin Cases. 2014; 2(9):422-425. 
[5]	MADER R, NOVOFESTOVSKI I, ADAWI M, et al. Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum. 2009;38(5):361-365. 
[6]	OKADA E, ISHIHARA S, AZUMA K, et al. Metabolic Syndrome is a Predisposing Factor for Diffuse Idiopathic Skeletal Hyperostosis. Neurospine. 2021;18(1):109-116. 
[7]	SETHI A, RUBY JG, VERAS MA, et al. Genetics implicates overactive osteogenesis in the development of diffuse idiopathic skeletal hyperostosis. Nat Commun. 2023; 14(1):2644. 
[8]	WEIR CB, JAN A. BMI Classification Percentile And Cut Off Points. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. 
[9]	MOHAMMED MS, SENDRA S, LLORET J, et al. Systems and WBANs for Controlling Obesity. J Healthc Eng. 2018;2018:1564748. 
[10]	SAKLAYEN MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018;20(2):12. 
[11]	COACCIOLI S, FATATI G, DI CATO L, et al. Diffuse idiopathic skeletal hyperostosis in diabetes mellitus, impaired glucose tolerance and obesity. Panminerva Med. 2000;42(4):247-251. 
[12]	刘小康,郭海龙,鲍丰,等.弥漫性特发性骨肥厚症的危险因素分析[J].临床骨科杂志,2024,27(1):20-24.  
[13]	EMDIN CA, KHERA AV, KATHIRESAN S. Mendelian Randomization. JAMA. 2017; 318(19):1925-1926. 
[14]	KURKI MI, KARJALAINEN J, PALTA P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508-518. 
[15]	DAVIES NM, HOLMES MV, DAVEY SMITH G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. 
[16]	PRITCHARD JK, PRZEWORSKI M. Linkage disequilibrium in humans: models and data. Am J Hum Genet. 2001;69(1):1-14. 
[17]	PARK JH, WACHOLDER S, GAIL MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570-575. 
[18]	BRION MJ, SHAKHBAZOV K, VISSCHER PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013;42(5):1497-1501. 
[19]	BURGESS S, THOMPSON SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-389. 
[20]	BOWDEN J, DEL GRECO MF, MINELLI C, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783-1802. 
[21]	BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525. 
[22]	VERBANCK M, CHEN CY, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-698. 
[23]	HARTWIG FP, DAVEY SMITH G, BOWDEN J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-1998. 
[24]	BRIKMAN S, LUBANI Y, MADER R, et al. High prevalence of diffuse idiopathic skeletal hyperostosis (DISH) among obese young patients - A retrospective observational study. Semin Arthritis Rheum. 2024;65:152356. 
[25]	HARLIANTO NI, WESTERINK J, FOPPEN W, et al. Visceral Adipose Tissue and Different Measures of Adiposity in Different Severities of Diffuse Idiopathic Skeletal Hyperostosis. J Pers Med. 2021;11(7):663. 
[26]	CHAPUT CD, SIDDIQUI M, RAHM MD. Obesity and calcification of the ligaments of the spine: a comprehensive CT analysis of the entire spine in a random trauma population. Spine J. 2019;19(8):1346-1353. 
[27]	FURUKAWA S, FUJITA T, SHIMABUKURO M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752-1761. 
[28]	DAN LANTSMAN C, HERMAN A, VERLAAN JJ, et al. Abdominal fat distribution in diffuse idiopathic skeletal hyperostosis and ankylosing spondylitis patients compared to controls. Clin Radiol. 2018;73(10):910.e15-910.e20. 
[29]	AHMED O, RAMACHANDRAN K, PATEL Y, et al. Diffuse Idiopathic Skeletal Hyperostosis Prevalence, Characteristics, and Associated Comorbidities: A Cross-Sectional Study of 1815 Whole Spine CT Scans. Global Spine J. 2024;14(4):1201-1209. 
[30]	HIROTA R, TERAMOTO A, YOSHIMOTO M, et al. Osteophyte Bridge Formation Correlates with Vascular Calcification and Cardiovascular Disease in Diffuse Idiopathic Skeletal Hyperostosis. J Clin Med. 2023;12(16):5412. 
[31]	ZINCARELLI C, IERVOLINO S, DI MINNO MN, et al. Diffuse idiopathic skeletal hyperostosis prevalence in subjects with severe atherosclerotic cardiovascular diseases. Arthritis Care Res (Hoboken). 2012;64(11):1765-1769. 
[32]	OUDKERK SF, MOHAMED HOESEIN FAA, PTHM MALI W, et al. Subjects with diffuse idiopathic skeletal hyperostosis have an increased burden of coronary artery disease: An evaluation in the COPDGene cohort. Atherosclerosis. 2019;287:24-29. 
[33]	ORDEN AO, DAVID JM, DÍAZ RP, et al. Association of diffuse idiopathic skeletal hyperostosis and aortic valve sclerosis. Medicina (B Aires). 2014;74(3):205-209.  
[34]	JULKUNEN H, AROMAA A, KNEKT P. Diffuse idiopathic skeletal hyperostosis (DISH) and spondylosis deformans as predictors of cardiovascular diseases and cancer. Scand J Rheumatol. 1981;10(3):241-248.   
[35]	MADER R, LAVI I. Diabetes mellitus and hypertension as risk factors for early diffuse idiopathic skeletal hyperostosis (DISH). Osteoarthritis Cartilage. 2009;17(6):825-828. 
[36]	DENKO CW, MALEMUD CJ. Body mass index and blood glucose: correlations with serum insulin, growth hormone, and insulin-like growth factor-1 levels in patients with diffuse idiopathic skeletal hyperostosis (DISH). Rheumatol Int. 2006;26(4):292-297. 
[37]	FASSIO A, ADAMI G, IDOLAZZI L, et al. Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. Calcif Tissue Int. 2021;108(2):231-239. 
[38]	PARIENTE E, PINI SF, OLMOS JM, et al. Early stages of diffuse idiopathic skeletal hyperostosis (DISH) and chronic inflammation: the Camargo Cohort Study. Clin Rheumatol. 2023;42(7):1931-1942. 
[39]	DĄBROWSKI M, KUBASZEWSKI Ł. Diffuse Idiopathic Skeletal Hyperostosis of Cervical Spine with Dysphagia-Molecular and Clinical Aspects. Int J Mol Sci. 2021;22(8):4255. 
[40]	MADER R, PAPPONE N, BARALIAKOS X, et al. Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. Curr Rheumatol Rep. 2021;23(1):6. 
[41]	MADER R, NOVOFASTOVSKI I, SCHWARTZ N, et al. Serum adiponectin levels in patients with diffuse idiopathic skeletal hyperostosis (DISH). Clin Rheumatol. 2018;37(10):2839-2845. |